# Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

> **NCT00111839** · PHASE2 · COMPLETED · sponsor: **EMD Serono** · enrollment: 150 (actual)

## Conditions studied

- Lung Cancer
- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Matuzumab

## Key facts

- **NCT ID:** NCT00111839
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-31
- **Primary completion:** 2007-07-31
- **Final completion:** 2009-03-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111839, "Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00111839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*